| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communication |
1 From the Department of Nutrition, the School of Public Health, the School of Medicine, the University of North Carolina, Chapel Hill; the Research Triangle Institute, Research Triangle Park, NC; and the Chemopreventive Agent Development Research Group, the Division of Cancer Prevention, the National Cancer Institute, Rockville, MD.
Background: Soy isoflavones are potential cancer chemoprevention treatments.
Objective: We conducted safety studies of purified unconjugated genistein, daidzein, and glycitein, and defined pharmacokinetic parameters for their absorption and metabolism.
Design: Thirty healthy men ingested a single dose of 1 of 2 isoflavone preparations purified from soy. The delivered doses of genistein (1, 2, 4, 8, or 16 mg/kg body wt) were higher than those previously administered to humans. Formulation A was composed of 90 ± 5% genistein, 10% daidzein, and 1% glycitein. Formulation B was composed of 43% genistein, 21% daidzein, and 2% glycitein.
Results: We observed no clinically significant behavioral or physical changes after treatment. We observed elevations in lipoprotein lipase and hypophosphatemia that were possibly related to the treatment but that were associated with no clinical toxicity. Considerable quantities of isoflavones were excreted in urine as conjugates. The terminal elimination rate, elimination half-life, area under the curve, maximum plasma concentration, apparent systemic clearance, and volume of distribution were estimated for genistein and daidzein. The mean elimination half-lives with both formulations were 3.2 h for free genistein and 4.2 h for free daidzein. The mean pseudo half-lives were 9.2 h for total genistein and 8.2 h for total daidzein.
Conclusions: Dietary supplements of purified unconjugated isoflavones administered to humans in single doses exceeding normal dietary intake manyfold resulted in minimal clinical toxicity. Genistein and daidzein (free and total) were rapidly cleared from plasma and excreted in urine.
Key Words: Genistein • daidzein • soy isoflavones • cancer • toxicity • pharmacokinetics • healthy men • North Carolina
This article has been cited by other articles:
|
|
 |
|
  S. W. J. Wang, K. H. Kulkarni, L. Tang, J. R. Wang, T. Yin, T. Daidoji, H. Yokota, and M. Hu Disposition of Flavonoids via Enteric Recycling: UDP-Glucuronosyltransferase (UGT) 1As Deficiency in Gunn Rats Is Compensated by Increases in UGT2Bs Activities J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1023 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. C. Hanwell, C. D. Kay, J. W. Lampe, B. J. Holub, and A. M. Duncan Acute Fish Oil and Soy Isoflavone Supplementation Increase Postprandial Serum (n-3) Polyunsaturated Fatty Acids and Isoflavones but Do Not Affect Triacylglycerols or Biomarkers of Oxidative Stress in Overweight and Obese Hypertriglyceridemic Men J. Nutr., June 1, 2009; 139(6): 1128 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Gleason, C. M. Carlsson, J. H. Barnet, S. A. Meade, K. D. R. Setchell, C. S. Atwood, S. C. Johnson, M. L. Ries, and S. Asthana A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women Age Ageing, January 1, 2009; 38(1): 86 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, Z. Wang, D. Kong, R. Li, S. H. Sarkar, and F. H. Sarkar Regulation of Akt/FOXO3a/GSK-3{beta}/AR Signaling Network by Isoflavone in Prostate Cancer Cells J. Biol. Chem., October 10, 2008; 283(41): 27707 - 27716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Rufer, A. Bub, J. Moseneder, P. Winterhalter, M. Sturtz, and S. E Kulling Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1314 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Piazza, M. G. Privitera, B. Melilli, T. Incognito, M. R. Marano, G. M. Leggio, M. A. Roxas, and F. Drago Influence of inulin on plasma isoflavone concentrations in healthy postmenopausal women Am. J. Clinical Nutrition, September 1, 2007; 86(3): 775 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. El Touny and P. P. Banerjee Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype Carcinogenesis, August 1, 2007; 28(8): 1710 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Chen, M. L Nagpal, D. M Stocco, and T. Lin Effects of genistein, resveratrol, and quercetin on steroidogenesis and proliferation of MA-10 mouse Leydig tumor cells J. Endocrinol., March 1, 2007; 192(3): 527 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vrieling, M. A. Rookus, E. Kampman, J. M. G. Bonfrer, C. M. Korse, J. van Doorn, J. W. Lampe, A. Cats, B. J. M. Witteman, F. E. van Leeuwen, et al. Isolated Isoflavones Do Not Affect the Circulating Insulin-Like Growth Factor System in Men at Increased Colorectal Cancer Risk J. Nutr., February 1, 2007; 137(2): 379 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. J. Wang, J. Chen, X. Jia, V. H. Tam, and M. Hu Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties Drug Metab. Dispos., November 1, 2006; 34(11): 1837 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. El-Rayes, S. Ali, I. F. Ali, P. A. Philip, J. Abbruzzese, and F. H. Sarkar Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-{kappa}B Cancer Res., November 1, 2006; 66(21): 10553 - 10559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Xu and R. C. Bergan Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor beta-Mediated Activation of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-27-kDa Heat Shock Protein Pathway Mol. Pharmacol., September 1, 2006; 70(3): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Van Goor, K. S. Straley, D. Cao, J. Gonzalez, S. Hadida, A. Hazlewood, J. Joubran, T. Knapp, L. R. Makings, M. Miller, et al. Rescue of {Delta}F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1117 - L1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Ju, J. Fultz, K. F. Allred, D. R. Doerge, and W. G. Helferich Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice Carcinogenesis, April 1, 2006; 27(4): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cassidy, J. E. Brown, A. Hawdon, M. S. Faughnan, L. J. King, J. Millward, L. Zimmer-Nechemias, B. Wolfe, and K. D.R. Setchell Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods J. Nutr., January 1, 2006; 136(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, S. Wang, X. Jia, S. Bajimaya, H. Lin, V. H. Tam, and M. Hu DISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION Drug Metab. Dispos., December 1, 2005; 33(12): 1777 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Green, T. R. Foss, and J. W. Kelly Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis PNAS, October 11, 2005; 102(41): 14545 - 14550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Banerjee, Y. Zhang, S. Ali, M. Bhuiyan, Z. Wang, P. J. Chiao, P. A. Philip, J. Abbruzzese, and F. H. Sarkar Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer Cancer Res., October 1, 2005; 65(19): 9064 - 9072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Huang, S. Chen, L. Xu, Y. Liu, D. K. Deb, L. C. Platanias, and R. C. Bergan Genistein Inhibits p38 Map Kinase Activation, Matrix Metalloproteinase Type 2, and Cell Invasion in Human Prostate Epithelial Cells Cancer Res., April 15, 2005; 65(8): 3470 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Manach, G. Williamson, C. Morand, A. Scalbert, and C. Remesy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 230S - 242S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jia, J. Chen, H. Lin, and M. Hu Disposition of Flavonoids via Enteric Recycling: Enzyme-Transporter Coupling Affects Metabolism of Biochanin A and Formononetin and Excretion of Their Phase II Conjugates J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1103 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Takimoto, K. Glover, X. Huang, S. A. Hayes, L. Gallot, M. Quinn, B. D. Jovanovic, A. Shapiro, L. Hernandez, A. Goetz, et al. Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1213 - 1221. [Abstract] [Full Text]
|
|
|
|
|
|
M. Hu, K. Krausz, J. Chen, X. Ge, J. Li, H. L. Gelboin, and Frank. J. Gonzalez IDENTIFICATION OF CYP1A2 AS THE MAIN ISOFORM FOR THE PHASE I HYDROXYLATED METABOLISM OF GENISTEIN AND A PRODRUG CONVERTING ENZYME OF METHYLATED ISOFLAVONES Drug Metab. Dispos., July 1, 2003; 31(7): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, H. Lin, and M. Hu Metabolism of Flavonoids via Enteric Recycling: Role of Intestinal Disposition J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1228 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T Bloedon, A R. Jeffcoat, W. Lopaczynski, M. J Schell, T. M Black, K. J Dix, B. F Thomas, C. Albright, M. G Busby, J. A Crowell, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women Am. J. Clinical Nutrition, November 1, 2002; 76(5): 1126 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nestel Role of Soy Protein in Cholesterol-Lowering: How Good Is It? Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1743 - 1744. [Full Text] [PDF]
|
|
|
|
|
|
N. Tsunoda, S. Pomeroy, and P. Nestel Absorption in Humans of Isoflavones from Soy and Red Clover Is Similar J. Nutr., August 1, 2002; 132(8): 2199 - 2201. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
